Skip to content
ClinCalc Pro
Menu
Soluble Guanylate Cyclase (sGC) Stimulator — PAH / CTEPH

Riociguat

Brand names: Adempas

Riociguat is an oral pulmonary vasodilator licensed for pulmonary arterial hypertension and for inoperable or persistent chronic thromboembolic pulmonary hypertension, used under specialist supervision.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a soluble guanylate cyclase stimulator that acts both directly on the enzyme and by sensitising it to endogenous nitric oxide, raising cyclic GMP to relax pulmonary vascular smooth muscle.

Prescribing in practice

  • Contraindicated in pregnancy and with concomitant phosphodiesterase type 5 inhibitors (such as sildenafil) or nitrates, because of the risk of profound, potentially fatal hypotension — pregnancy prevention measures are mandatory for women of childbearing potential.
  • It is contraindicated in pulmonary hypertension associated with idiopathic interstitial pneumonias, and smoking lowers plasma levels so dose may need review if smoking status changes.
  • Up-titrate gradually against systolic blood pressure and symptoms of hypotension, and avoid in severe hepatic impairment.

Monitoring

Monitor blood pressure during dose titration and at intervals thereafter, watching for symptomatic hypotension and haemoptysis or pulmonary haemorrhage.

Counselling the patient

  • Effective contraception is essential and monthly pregnancy testing may be required.
  • Never take with erectile dysfunction medicines or nitrates.
  • Report dizziness, fainting or coughing up blood.

Evidence & guidelines

Efficacy in both pulmonary arterial and chronic thromboembolic pulmonary hypertension is supported by pivotal randomised trials and reflected in the SPC.

Reference: PATENT-1 Trial; CHEST-1 Trial; NICE TA401 (Riociguat for PAH and CTEPH); ESC/ERS PAH Guidelines 2022; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.